Recombinant interferon gamma for the therapy of immunological and oncological diseases.

J Biotechnol

Boehringer Ingelheim R + D Vienna, Austria.

Published: April 1996

Download full-text PDF

Source
http://dx.doi.org/10.1016/0168-1656(96)80466-4DOI Listing

Publication Analysis

Top Keywords

recombinant interferon
4
interferon gamma
4
gamma therapy
4
therapy immunological
4
immunological oncological
4
oncological diseases
4
recombinant
1
gamma
1
therapy
1
immunological
1

Similar Publications

Recombinant VSVs: A Promising Tool for Virotherapy.

Acta Naturae

January 2024

Sirius University of Science and Technology, Krasnodar Region, Sirius Federal Territory, 354340 Russian Federation.

Cancer is one of the leading causes of death worldwide. Traditional cancer treatments include surgery, radiotherapy, and chemotherapy, as well as combinations of these treatments. Despite significant advances in these fields, the search for innovative ways to treat malignant tumors, including the application of oncolytic viruses, remains relevant.

View Article and Find Full Text PDF

Background: In this article, we present the results of a multicenter clinical trial of IFN-γ in patients with drug-susceptible and drug-resistant pulmonary Tuberculosis (TB) in routine clinical practice.

Objective: This study aimed to confirm the efficacy and safety of IFN-γ administered to patients with TB.

Methods: All patients were diagnosed with TB after being tested by bacterioscopic and molecular genetic methods and had no contraindications to standard chemotherapy.

View Article and Find Full Text PDF

Exploring using HBsAg to predict interferon treatment course to achieve clinical cure in chronic hepatitis B patients: a clinical study.

Front Immunol

January 2025

Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, Tianjin, China.

Objective: Although pegylated interferon α-2b (PEG-IFN α-2b) therapy for chronic hepatitis B has received increasing attention, determining the optimal treatment course remains challenging. This research aimed to develop an efficient model for predicting interferon (IFN) treatment course.

Methods: Patients with chronic hepatitis B, undergoing PEG-IFN α-2b monotherapy or combined with NAs (Nucleoside Analogs), were recruited from January 2018 to December 2023 at Tianjin Third Central Hospital.

View Article and Find Full Text PDF

Bacteriophage M13KE as a Nanoparticle Platform to Display and Deliver a Pathogenic Epitope: Development of an Effective Porcine Epidemic Diarrhoea Virus Vaccine.

Microb Pathog

January 2025

Shanghai Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai 201100, China. Electronic address:

Porcine epidemic diarrhoea virus (PEDV) is a porcine enteric coronavirus, outbreaks and epidemics of which have caused huge economic losses to the livestock industry. The disadvantage of existing PEDV vaccines is that the unstable efficacy and high cost limit their widespread use. Therefore, there is an urgent need to develop a recombinant transgenic vaccine candidate for PEDV.

View Article and Find Full Text PDF

Alginate-polylysine-alginate (APA) microencapsulated transgenic human amniotic epithelial cells ameliorate fibrosis in hypertrophic scars.

Inflamm Res

January 2025

Department of Burns and Cutaneous Surgery, Xijing Hospital, Air Force Medical University, No.127 Changle West Road, Xincheng District, Xi'an, 710032, Shaanxi, China.

Background: Hypertrophic scar (HS) is a severe skin fibrosis. Transplanting stem cells carrying anti-fibrotic cytokine genes, like interferon-gamma (IFN-γ), is a novel therapeutic strategy. Human amniotic epithelial cells (hAECs) are ideal seed cells and gene vectors.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!